Phosphodiesterase 4 Inhibition Reduces Innate Immunity and Improves Isoniazid Clearance of Mycobacterium tuberculosis in Infected Mice
Author Information
Author(s): Koo Mi-Sun, Manca Claudia, Yang Guibin, O'Brien Paul, Sung Nackmoon, Tsenova Liana, Subbian Selvakumar, Fallows Dorothy, Muller George, Ehrt Sabine, Kaplan Gilla
Primary Institution: Laboratory of Mycobacterial Immunity and Pathogenesis, The Public Health Research Institute Center at the University of Medicine and Dentistry of New Jersey
Hypothesis
Selective modulation of the host immune response to modify the environmental pressure on the bacilli may result in better bacterial clearance during TB treatment.
Conclusion
The combination of the immune modulator CC-3052 with isoniazid treatment improved bacillary clearance and reduced lung pathology in mice infected with Mycobacterium tuberculosis.
Supporting Evidence
- CC-3052 treatment improved bacillary clearance in the lungs of infected mice.
- Combination treatment resulted in smaller granulomas and less lung pathology compared to isoniazid alone.
- CC-3052 did not have a direct bactericidal effect on Mycobacterium tuberculosis.
Takeaway
Researchers found that a drug called CC-3052 can help another drug, isoniazid, work better against a germ that causes tuberculosis in mice.
Methodology
Mice infected with Mycobacterium tuberculosis were treated with isoniazid and the phosphodiesterase 4 inhibitor CC-3052, and bacillary clearance was measured over time.
Potential Biases
Potential bias due to the involvement of Celgene Corporation, which provided the drug for the study.
Limitations
The study did not evaluate the ability of co-treatment with CC-3052 plus isoniazid to achieve sterilization of the bacilli.
Participant Demographics
B6D2F1 mice were used in the study.
Statistical Information
P-Value
0.016
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website